









THE MOLECULAR TYPING OF HUMAN 
PAPILLOMAVIRUSES FROM PATIENTS WITH 
INVASIVE CARCINOMA OF THE CERVIX IN 
CAP~TOWN 
Nicola Susan Brink 
A dissertation submitted to the Faculty of Medicine, 
University of Cape Town, in partial fulfillment 
of the requirements for the degree of 
Master of Medicine (Virology) 
The University nf Cape Town has been g!ven 
the right to reproduce th:s thesis in who4e 
or in part. Copyrigl"lt is hold by the auth~. --------------· 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 











THE MOLECULAR TYPING OF HUMAN 
PAPILLOMA VIRUSES FROM PATIENTS WITH 
INVASIVE CARCINOMA OF THE CERVIX IN 
CAPETOWN 
Nicola Susan Brink 
A dissertation submitted to the Faculty of Medicine, 
University of Cape Town, in partial fulfillment 
of the requirements for the degree of 
Master of Medicine (Virology) 
Abstract 
South Africa has one of the highest incidences of carcinoma of the cervix in the 
world. The incidence of HPV infection in So~th African patients with invasive 
carcinoma of the cervix, as well as the types of HPV involved is unknown. 
Biopsies were obtained from consecutive patients with invasive carcinoma of the 
cervix presenting to the Combined Assessment Clinic at Groote Schuur Hospital, 
Cape Town. 
HPV DNA was detected by Southern blot hybridization in a total of 38/86 patients 
with invasive carcinoma of the cervix in Cape Town. HPV 16 DNA was detected in 
a total of 13/86 (15 % ) patients. Although this is somewhat lower than has been 
reported in many studies, a geographical variation in the prevalence of HPV 16 in 
different countries is well documented. 
The application of a more sensitive technique, the polymerase chain reaction, 
increased the detection of HPV 16 DNA to 16/86. The polymerase chain reaction 
did not, however, significantly increase the detection of HPV 16 DNA 
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1. Introduction 
Cancer of the cervix is the most common cancer amongst women world-wide and 
in developing countries it ranks as the most common form of cancer. (Armstrong, 
1988). About 500 000 new cases of carcinoma of the cervix are diagnosed world-
wide annually.(Shah and Howley, 1990). The pattern in South Africa follows that 
observed in developing countries. Cervical cancer is the most common cancer 
among women in South Africa with an incidence of 0,6/1000 among black women 
aged 15 - 65 years. (Cronje, 1989). 
Epidemiological evidence suggests that carcinoma of the cervix is the consequence 
of a genital infection. In 1842 an Italian physician, Rigoni-Stem, noted that 
carcinoma of the cervix was rare among nuns and was more frequently found in 
married women as compared to unmarried women.(Melnick et al., 1989). The 
association of this disease with certain unique risk factors such as multiple sexual 
partners and age of first intercourse, suggested that carcinoma of the cervix 1s 
possibly caused by a sexually transmitted infectious agent. (Rotkin, 1973). 
The aetiology of carcinoma of the cervix has been the subject of intense speculation 
over the past two decades with possible candidates including non-infectious factors 
such as spermatozoa and a variety of infectious agents including Trichomonas 
vaginalis and herpes simplex virus. (Melnick et al., 1989). The role of 
papillomaviruses as a possible candidate in the aetiology of carcinoma of the cervix 
was first proposed in 1974 by zur Hausen. (zur Hausen, 1987). The 
papillomaviruses are a highly heterogeneous group of DNA viruses some of which 
have been associated with naturally occurring cancers. (Shah and Howley, 1990 ). 
This recognition that human papillomavirus (HPV) types are closely linked to 
certain cancers has focused interest on a specific subgroup of human 
papillomaviruses found in the genital tract and especially those types associated 
with carcinoma of the cervix 
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1.1. The Virus 
1.1.1. General. 
The papillomaviruses are grouped together with the polyomaviruses to form the 
papovavirus family. The papillomaviruses are larger than the polyomaviruses 
measuring 55 nm in diameter. Each virion contains a double-stranded DNA 
molecule. (Pfister, 1987a). A detailed knowledge of the structure and biological 
properties of the virus is necessary in understanding the role of HPV in the genesis-
of cancer. 
1.1.2. Classification and nomenclature 
Papillomaviruses are classified firstly according to their natural host, with most 
papillomaviruses having a very restricted host range. Further classification into 
different types is according to the genetic relatedness of the viral genome. (Coggin 
and zur Hausen, 1979). If two papillomaviruses show less than 50% hybridization 
in liquid reassociation kinetics they are defined as different types, so that HPV 6 
and HPV 11, which have an overall nucleotide sequence homology of 82 % but give 
a value of 25 % in liquid reassociation kinetics, are classified as different types. 
(Howley, 1990). To date 60 distinct HPV types have been described. (De Villiers, 
1989) Subtypes are assigned if a new isolate has more than 50% but less than 
complete homol_ogy with a known HPV type. (Coggin and zur Hausen, 1979). 
1.1.3. Genetic Organization 
The human papillomaviruses have a circular double stranded DNA genome of 
approximately 8000 base pairs (bp). All the open reading frames (ORF) are 
characteristically located on the same DNA strand. (Petterson et al., 1987). 
Comparison of 10 papillomaviruses whose complete DNA sequences have been 
determined show that they share a similar genetic arrangement. (Giro and Danos, 
1986). The open reading frames involved in cell transformation and DNA 
replication are called "early" or "E" ORFs and those coding for virion structural 
proteins are called "late" or "L" ORFs. Between the early and late ORFs there is a 
non-coding regulatory region of approximately 1000 bp which contains the 
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regulatory regions. (Campo, 1988). Specific functions have been assigned to some 
of the individual papillomavirus open reading frames. El is thought to be necessary 
for episomal (plasmid) replication, E2 for regulation of transcription and E4 codes 
for a late cytoplasmic protein. The functions of E3 and E8 are not yet known. E5, 
E6 and E7 are involved in transformation. Ll and L2 code for the capsid proteins 
of the virus. (Shah and Howley, 1990). 
LCR E6 E7 --...... "' 
7904/1 
E1 
6000 HPV-16 2000 
ES 
Fi&nre 1. The genomic map of HPV 16. The "early" open reading frames are 
designated El - E7, the "late" open reading frames Ll and L2 and the long 
control region as the LCR. (Modified from Shah and Howley, 1990). 
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1.1.4. Biological properties 
Papillomaviruses display a high degree of species and tissue specificity. Human 
papillomaviruses infect the epithelium of the skin and mucous membranes 
producing epithelial tumours. On this basis they can be divided into cutaneous and 
mucosal types. These tumours show limited growth and often regress 
spontaneously. The virus probably enters the skin through microscopic lesions and 
infects the basal cells. The persisting viral genome either increases the rate of cell 
proliferation or prolongs the normal lifespan of the cell, both of which lead to 
hyperplasia and the formation of a wart. (Pfister, 1987b). Epidermal cells are not 
permissive for DNA replication at the beginning of the differentiation process and 
the initiation of viral DNA replication only occurs in keratinising cells. Viral 
replication is therefore linked to the differentiation of the squamous epithelial cell. 
(Taichman and LaPorta, 1987). The virus may also infect mucosal surfaces. 
Proliferating cells are exposed at the squamo-columnar junction of the uterine 
cervix and most of the cervical HPV infections occur at this site. (Pfister, 1987b). 
Abnormal cellular differentiation, for example in malignancy, is sometimes 
accompanied by a non-productive infection. This feature is demonstrated in figure 
2. 
Viral assembly 




Carcinoma (abnormal Cell 
differentiation) 
Benign transformation t 
of Keratinocytes 
... I -----1•~ Formation of Papilloma ---- Certain PV types involved 
in progression to malignancy 
Fi20re 2. Illustration of the replication cycle of papillomaviruses. (Modified 
from Taichman and LaPorta, 1987). 
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1.2. The Spectrum of Disease caused by HPV 
The human papillomaviruses comprise three clincopathological groups -
cutaneotropic types found in immunologically normal individuals, cutaneotropic 
viruses causing multiple warts and dry scaly flat lesions in patients with 
Epidermodysplasia verruciformis and mucosatropic viruses infecting the genital, 
oral and respiratory mucosa. (Pfister, 1987a). 
1.2.1. Genital HPV infection 
The spectrum of clinical manifestations of genital HPV infections includes both 
benign and malignant lesions of the cervix , vulva and penis. In addition HPV 16 
DNA has been demonstrated in normal cervical tissue. ( de Villiers et al., 1987; 
Gergety et al., 1987). Classical condylomata are probably the most frequently 
recognized clinical manifestation of genital HPV infections. However, various 
studies have shown an association between HPV and cervical intraepithelial 
neoplasia (CIN) (de Villiers et al., 1987; Crum et al., 1984) and this association 
has been the subject of extensive research over the past decade. 
1.2.2. Carcinoma of the cervix 
The association of HPV with carcinoma of the cervix was first proposed about 18 
years ago, but has been difficult to prove its validity as it is neither possible to 
_grow the virus in vitro, nor are there reliable serological tests to detect current or 
past infection with HPV. (zur Hausen, 1987). The cloning of genomes of 
papillomaviruses into plasmids for use as molecular probes enabled the 
identification of specific HPV nucleotide sequences in a proportion of cervical 
cancers, as well as in cervical cancer cell lines. Although sixty different HPV types 
have been identified, only HPV types 16, 18, 31, 33, 35, 45, 51, 52, 56 and 58 
have been isolated from patients with cervical intraepithelial neoplasia (CIN) or 
cervical carcinoma. HPV types 6, 11, 30, 34, 40, 42, 43, 44 and 57 were not 
originally isolated from patients with genital malignancies, but have been found 
rarely in cases with CIN and cervical carcinoma. (De Villiers, 1989). 
HPV 16 DNA was first demonstrated in a biopsy sample from a patient with 
invasive carcinoma of the cervix by Durst et al., 1983. These workers showed that 
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there were nucleotide sequences in the biopsy material which hybridized with HPV 
type 11 DNA under non-stringent conditions. The DNA from this biopsy was not 
homologous with other HPV types. Initial studies showed that 11/18 cervical cancer 
samples from German patients contained sequences which hybridized with HPV 16 
DNA under conditions of high stringency. (Durst et al., 1983). 
In 1984 Boshart and colleagues reported the isolation and partial characterization of 
a new type of HPV, HPV 18 from a cervical cancer biopsy. HPV 18 DNA was 
originally detected in 9/36 cervical carcinomas from Africa and Brazil and 2/13 
cervical tumours from Germany. In addition HPV 18 DNA was found in cells of 
the HeLa, KB and C4-1 cell lines, all of which are derived from cervical 
carcinomas. (Boshart et al., 1984) 
In 1986 the molecular cloning and characterization of HPV 33 was reported as an 
additional potentially oncogenic HPV. (Beaudenon et al., 1986) Other reports have 
appeared in the literature identifying specific HPV types in association with cervical 
neoplasia (Kahn et al., 1986; Lorincz et al., 1986; Naghashfar et al., 1987; Nuovo 
et al., 1988; Shimoda et al., 1988; Yajima et al., 1988 and Lorincz et al., 1989). 
In spite of the increasing number of different HPV types associated with carcinoma 
of the cervix, HPV types 16, 18 and 33 are most commonly associated with 
malignant change. Some doubt has, however, been cast on the aetiological role of 
HPV in carcinoma of the cervix by the demonstration of HPV 16 in 84 % of women 
with normal cervical cytology using the more sensitive polymerase chain reaction. 
(Tidy et al., 1989a). Tidy and his colleagues proposed the existence of a less 
oncogenic subtype of HPV 16 which they termed HPV type 16b. HPV 16b was 
thought to contain a 21bp deletion within the upstream regulatory region. It was 
proposed that this deletion removed a pair of E2 consensus binding sites. The E2 
protein requires two binding sites in close proximity to mediate its transactivating 
function. (Tidy et al., .1989b). The proposed existence of a less oncogenic subtype 
of the HPV 16 prototype provided a plausible explanation for the demonstration of 
HPV 16 in normal cervical tissue. However, doubts were cast on the existence of 
HPV 16b when other workers were unable to reproduce the results of Tidy and his 
co-workers. On reinvestigation of the original samples it was found that accidental 
contamination of the original DNA samples with products of an earlier PCR 
reaction had occurred. The findings were retracted. (Tidy et al., 1989c) . 
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1.3. Epidemiological evidence : HPV and Carcinoma of the cervix. 
In contrast to the experimental evidence linking HPV to carcinoma of the cervix, 
epidemiological evidence supporting this association is only now accumulating.In 
the past studies were often numerically small and either included inappropriate 
controls or were completely lacking controls. A further problem with many 
comparative studies was the use of different sampling methods for cases and 
controls. Biopsies were usually analyzed from cervical cancer patients whilst 
cytological specimens were often used for the control group. To convincingly 
demonstrate the association of HPV infection with carcinoma of the cervix it would 
be necessary to prospectively follow a large group of randomly selected women, 
examined for HPV infection and characterized for other risk factors, and to 
determine the incidence rate for carcinoma of the cervix. This is obviously not 
possible because of ethical considerations. (Munoz et al., 1988). An alternative 
would be to use case/control studies to compare the prevalence of HPV infection in 
women with cancer of the cervix and women with normal cervices. (Munoz et al., 
1988). 
A multicenter case/control study in Latin America of 756 cases of invasive 
carcinoma of the cervix and 1467 randomly selected age-matched controls showed 
that cervical infection with HPV 16 or 18 was strongly associated with cervical 
cancer. The presence of HPV DNA was detected using filter in situ hybridization. 
Seven hundred and fifty nine cases of invasive cancer of the cervix and 1466 
randomly selected age matched controls were included in the study. Sixty-two 
percent of the cases had HPV 16/18 DNA compared to 32 percent of randomly 
selected controls. (Reeves et al., 1989). 
A further study suggested that the use of primer directed enzymatic amplification of 
specific target DNA sequences (the polymerase chain reaction) may be a useful 
epidemiological tool in investigating cervical HPV infection. In this study the 
authors demonstrated that 36/38 women with cytological abnormalities were 
infected with HPV 16. However 7/10 women with no cytological abnormality were 
also infected with HPV type 16, or a combination of HPV types 16 and 11, which 
suggests that HPV infection may be more common than previously suspected. 
(Young et al., 1989). The polymerase chain reaction may be used for large scale 
epidemiological studies in the future. 
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1.4. Papillomaviruses and Malignancy 
Papillomaviruses have been implicated in the development of squamous cell 
carcinomas in man and animals, but proving a causal relationship between a virus 
and a human cancer may be extremely difficult. Firstly, there may be a long latent 
period between the viral infection and the development of a cancer, and secondly, 
there is often a low prevalence of cancer amongst infected individuals. (Henderson, 
1989). 
The role of papillomaviruses in the development of genital malignancies has been 
extensively investigated. The papillomaviruses are a highly heterogeneous group of 
viruses, but despite the multiplicity of HPV types only a few types have been 
associated with naturally occurring cancers. (Campo, 1988). This observation has 
led to the hypothesis that some HPV have a "more malignant" potential than others. 
However, no obvious differences have been found in the genomic organization of 
the "more malignant" types. Comparison of 10 papillomaviruses whose complete 
sequences have been determined show that they share a similar genetic plan. (Giro 
and Danos, 1986). Alternatively it ha_s been speculated that the greater malignant 
potential could be due to more subtle genetic differences or a greater propensity of 
the target cell for malignant transformation, or both. This is best illustrated by 
bovine papillomavirus 2 (BPV 2) which is strongly associated with neoplastic 
transformation in the bladder of cattle, but produces only benign proliferations in 
the skin and esophagus. (Jarret et al., 1984). 
1.4.1. Cellular transformation 
Experimental work using bovine papillomavirus (BPV) has shown that both BPV-1 
or its DNA can transform mouse fibroblasts in culture and that the morphologically 
transformed cells are tumorigenic for- nude mice. (Dvoretzky et al., 1980). The 
transforming activity has been localized to a fragment containing 69% of the bovine 
papillomavirus genome (Campo, 1988). Sequence analysis by Chen and his co-
workers showed that this fragment contains the "early" ORFs and the non-coding 
regulatory region. (Chen et al., 1982). The transforming function of the 
papillomaviruses has thus been clearly demonstrated, but the role of the virus in the 
progression to malignancy and the maintenance of the malignant state is less clear. 
(Campo, 1988). It is possible that papillomaviruses may prime the epithelium for 
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malignant change, but progression to the full malignant phenotype is dependent on 
co-factors (see below). 
1.4.2. The physical state of the viral DNA 
Early studies showed that the physical state of the viral DNA within the host cell is 
probably important in the development of papillomavirus associated malignancies. 
An analysis of the physical state of the viral DNA in cervical carcinoma tissue and 
derived cell lines, showed that the viral DNA is usually integrated into the host cell 
genome.(Durst et al., 1985). It has been generally accepted that integration of HPV 
DNA usually results in interruption of the El or E2 ORFs of the viral genome with 
preferential retention of the LCR/E6/E7 region (see figure 1). E6 and E7 are 
thought to be essential in some stages of HPV induced cellular transformation. 
These genes may also be necessary for maintenance of the transformed phenotype. 
The long control region (LCR) contains promoter elements for early genes, a 
transcriptional enhancer and possibly the origin of replication of the virus. 
Therefore preferential retention of the LCR may be important in the development 
of the malignant phenotype either by ensuring continuous expression of the E6/E7 
genes or by cis or trans activation of cellular oncogenes. (Choo et al., 1987). 
However, recent studies of four clones of integrated HPV DNA showed that the 
interruptions of the viral genome occurred not only at the El/E2, but also at Ll/L2, 
indicating that there is no site specific for integration in the viral sequence. These 
investigators confirmed the retention of the E6/E7 and the LCR. (Wagatsukura et 
al., 1990). 
Controversy over the importance of the physical state of the viral DNA in the host 
cell has arisen from a recent report from Japan. These workers demonstrated that 
not only integrated but also episomal HPV DNA alone can be demonstrated in 
invasive carcinoma of the cervix. (Matsukura et al., 1989). In addition, integrated 
HPV viral sequences have also been found in normal tissue and low grade 
neoplastic tissue indicating the importance of additional co-factors in the 
development of malignancy. (Schneider-Maunoury et al., 1987). The importance of 
the physical state of the viral DNA within the host cell and the role of integrated 
viral DNA in the eventual progression to malignancy has therefore not been 
precisely defined. 
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1.4.3. Role of cellular oncogenes 
With the discovery that viral DNA may be integrated into the host cell genome in 
cervical cancer it has been postulated that cell transformation may occur by 
insertional mutagenesis with consequent activation of cellular oncogenes. The 
insertion of a foreign genetic element near to cellular oncogenes controlling growth 
could affect their expression and lead to uncontrolled cell growth. (Campo, 1988). 
In several different carcinoma cell lines the HPV DNA sequences have been 
localized to regions containing cellular oncogenes such as c-src, c-raf and c-myc. 
(Durst et al., 1987). In addition, amplification and rearrangements of the cellular 
oncogenes c-myc and c-Ha-ras have been observed in cervical cancers harbouring 
HPV genomes. (Campo, 1988). A study by Riou et al., 1987 examined biopsies 
from patients with invasive carcinoma of the cervix for the expression of c-myc 
proto-oncogene. Biopsies were obtained from 72 patients with untreated invasive 
carcinoma of the cervix. The expression of c-myc was analysed by Northern blot 
and slot blot hybridization of total RNA. C-myc over expression was associated 
with a poorer prognosis and an increased incidence of early relapse. Riou and his 
colleagues therefore proposed that analysis of c-myc RNA in biopsies from patients 
with cervical carcinoma could possibly identify patients at greater risk for early 
recurrence. (Riou et al., 1987). 
1.4.4. Role of HPV gene products 
As mentioned earlier the E6/E7 genes appear to be necessary for transformation. 
The E7 gene product possibly plays an important role in this process as the E7 
protein of HPV is capable of binding to the retinoblastoma (RB) gene protein. The 
retinoblastoma gene polypeptide is absent in retinoblastoma tumours of the eye and 
it has been postulated that this polypeptide may play a critical role in limiting the 
proliferation of certain cells. The binding of the E7 protein to the retinoblastoma 
gene polypeptide product may therefore be associated with increased cell 
proliferation and oncogenesis and may play a necessary role in multistep 
tumorigenesis. (Marx, 1989). Further work on the importance of specific viral gene 
products showed that the presence of anti-E7 antibodies in the sera from patients 
correlated with the presence of cervical malignancy. Jochmus-Kudielka and her co-
workers tested sera from patients with cervical cancer, patients with HPV 
associated lesions and patients attending hospital for reasons unrelated to HPV 
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infection for the presence of antibodies to HPV type 16 E4 and E7 proteins. The 
importance of the E7 protein in the development of cervical malignancy is 
highlighted above. The E4 protein was chosen because it was found to be most 
prominent in HPV induced skin warts. A significant association was demonstrated 
between the presence of antibodies to HPV E7 and the presence of cervical 
carcinoma. (Jochmus-Kudliekla et al., 1989). 
Differences between the oncogenic and non-oncogenic HPV types have been the 
subject of intense investigation. Gage and her co-workers demonstrated that the 
retinoblastoma (RB) protein preferentially binds to the phosphorylated form of HPV 
6b E7, which comprises only a minor fraction of the total E7 expressed in a 
transfected cell line. The E7 gene product of HPV 16 was shown to bind more 
extensively to the RB protein. These characteristics may help to explain the 
difference in the oncogenic potential of the oncogenic and non-oncogenic types of 
genital papillomaviruses. (Gage et al., 1990). 
1.4.5. Role of Cofactors 
The role of co-factors in the full expression of the malignant phenotype has been 
repeatedly emphasized. As mentioned above HPV 16 DNA can be demonstrated in 
normal tissue indicating the importance in additional factors in the progression to 
malignancy. A number of co-factors have been proposed in the development of 
cervical malignancy. 
Hormones appear to act as tumour promoting agents in their ability to enhance the 
incidence of cancer. Durst et al., 1989 demonstrated that hydrocortisone had a 
marked enhancing effect on Kirsten murine sarcoma virus (Ki-MSV) induced 
transformation in HPV 16 immortalized cells. (Durst et al., 1989). 
Smoking is an important risk factor in the development of genital cancer. Nicotine 
may give rise to the powerful carcinogens (N-nitrosomines) which have been 
demonstrated in vaginal fluids. (Pfister, 1987b). 
In 1982 zur Hausen proposed that genital cancer results from a "promoting" 
papillomavirus infection in combination with a variety of initiating events. The 
initiating event may be in the form of a HSV infection, but other cofactors such as 
smoking and hormonal influences may be important in genital cancer development 
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in papillomavirus infected tissue. The genetic predisposition of the host may also be 
important in the full expression of the malignant phenotype. (zur Hausen, 1982). 
He recently re-emphasized the importance of co-factors in the development of 
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Figure 3: Model of synergism between a "promoting" papillomavirus infection 
and "initiating" events (cofactors) eg. smoking with the progression to 
malignancy. (Modified from zur Hausen, 1982). 
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1.5. Diagnosis of HPV infection 
The diagnosis of HPV infection and research into the development of 
diagnostic tests are difficult as it is not possible to grow the virus in vitro, nor 
are there reliable serological tests. In addition, there are no satisfactory animal 
models for genital cancer. The human keratinocyte is the natural host for 
many HPV types, but keratinocytes are fastidious cells and are difficult to 
grow. Laboratory studies are therefore time consuming and require expertise. 
1.5.1. Cytology and Histology. 
Cells pathognomonic of HPV infection are known as koilocytes. These cells 
have an abnormal hyperchromatic nuclei surrounded by a zone of transparent 
cytoplasm. These light microscopic findings may provide useful information 
on the presence of HPV , but no information is obtained on the type of HPV. 
1.5.2. Electron Microscopy 
The success of electron microscopy in the diagnosis of HPV infection depends 
on the demonstration of viral particles. As viral expression and assembly takes 
place only in terminally differentiated cells, undifferentiated malignant cells 
do not usually contain HPV virions. (Caussy et al., 1988). This technique is 
therefore not suitable for the detection of HPV infections in cervical cancer 
cells. A further drawback is that the morphology of the different HPV types is 
identical and no information is therefore obtained on the type of HPV present. 
(Caussy et al., 1988). 
1.5.3. Immunocytochemistry 
Immunologic methods can be used to detect the presence of papillomavirus 
antigens by the peroxidase-anti-peroxidase method using primary antibodies 
to disrupted papillomavirus raised in rabbits. A major disadvantage of this 
method is that the commercially available antisera react with the group 
specific antigens of HPV and do not provide any information on the type of 
HPV present. (Roman and Fife, 1989). 
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1.5.4. Nucleic acid hybridization 
DNA hybridization is currently the only technique which types HPV. Several 
modifications of this technique are currently available. 
Southern Blot Hybridization 
Southern blot hybridization is considered the "gold standard". Total cellular DNA 
is extracted and digested with a restriction endonuclease. The initial enzyme used 
for HPV typing is usually Pstl. After digestion with this enzyme the specific PstI 
fragments are separated on an agarose gel. To detect the specific HPV fragments 
the DNA must be denatured, neutralized and transferred onto a nylon membrane by 
the process of Southern blotting. The nylon membrane is then probed with cloned 
HPV DNA. Disadvantages of this technique include the fact that it is extremely 
time consuming and requires relatively large amounts of DNA (10 ug) to achieve 
the desired sensitivity. Advantages include its sensitivity and specificity. In 
addition, it also provides suggestive information on the physical state of the viral 
DNA within the host cell, that is whether the viral DNA is present in an 
extrachromosomal or episomal form, or has integrated into the host cell 
chromosome as often occurs with malignancy. (Roman and Fife, 1989). 
Dot blot hybridization 
In this procedure the total cellular DNA is extracted from the biopsy, but it is not 
digested with a restriction endonuclease but applied directly to a nylon membrane. 
Dot blot hybridization has the advantage of being a relatively rapid procedure. It 
also requires less DNA than Southern blot hybridization. This technique must be 
adequately controlled to avoid false positive results. 
Reverse blot hybridization. 
In this technique the cellular DNA is radiolabeled and hybridized with known HPV 
types. The cloned HPV types are digested with the appropriate restriction 
endonuclease and the fragments are separated by gel electrophoresis. The DNA is 
then transferred onto a nylon membrane and probed with radiolabelled cellular 
DNA. (De Villiers et al., 1986). 
19 
Tissue in situ hybridization 
Tissue In situ hybridization has the advantage of providing information on the 
localization of the HPV genomes in the specimen. The DNA is not isolated from 
the specimen, but the tissue sections are probed directly. This technique can be 
used for paraffin sections and allow retrospective studies to be performed. 
(Beckman et al., 1985) . 
Filter in situ hybridization 
In this technique the cells are applied directly to a filter and disrupted on the filter. 
The DNA is then denatured and neutralized and hybridized with a cloned HPV 
probe. An advantage of this technique is that it allows detection of DNA in material 
from scrapings and smears. However, as with dot blot hybridization, this technique 
is also prone to false positive results. (De Villiers et al., 1987). 
1.5.5. The polymerase chain reaction. 
The polymerase chain reaction is a new and extremely powerful tool in the field of 
molecular biology. The technique selectively amplifies a specific target sequence of 
DNA. The amplification primers used in the reaction are oligonucleotides which 
flank the sequence of interest. The DNA extracted from the specimen is denatured 
and then allowed to anneal with the primers. In the presence of a DNA polymerase 
a new strand of DNA will be synthesized using the oligonucleotide as a primer. 
Repeated cycles of denaturing, annealing and primer extension allows the specific 
target sequence to be amplified. After amplification is completed the presence of 
the amplified target sequence should be confirmed. Knowledge of the target 
sequence makes it possible to predict the size of the amplified product. The size of 
the amplified product can be estimated by comparing it to a molecular weight 
marker on an agarose gel. The identity of the amplified sequence should be 
confirmed by hybridization. (Roman and Fife, 1989; Eisenstein, 1990). 
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2. Aim of the study 
Cancer of the cervix is the most common cancer among women in South Africa, 
with an incidence of 0,6/1000 among black women. (Cronje, 1989) No information 
is currently available on the frequency and types of human papillomaviruses found 
in patients with invasive carcinoma of the cervix in South Africa. A study by 
Williamson et al., 1989 showed that biopsies from 69% of patients with cervical 
intraepithelial neoplasia grade 3 (CIN 3) contained HPV DNA by Southern blot 
hybridization. (Williamson et al., 1989) This confirmed the presence of human 
papillomavirus infection in patients with premalignant genital lesions in our 
geographical region. 
The aim of this study was therefore to determine: 
1. The frequency of HPV infection in patients with invasive carcinoma of the 
cervix in patients attending the Gynaecological Oncology Clinic at Groote 
Schuur Hospital. 
2. The types of HPV present in these patients. 
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3. Methods 
3.1. Study population and sample collection 
Biopsies were obtained from 93 consecutive patients with invasive carcinoma of the 
cervix attending the Combined Assessment Clinic at Groote Schuur hospital. This 
clinic is run by members of the Radiotherapy and Gynaecology departments , as 
well as nursing staff, and provides a multidisciplinary approach to patients with 
genital malignancies. Punch biopsies were taken from the center of the cervical 
lesion by an experienced gynaecologist with a special interest in oncology. Each 
biopsy was divided in half. Half the biopsy was preserved in formalin for histology 
and the other half was transported without delay to the virology laboratory and 
stored at -100c for DNA extraction. 
Biopsies from 75 patients were histologically classified as squamous carcinoma with 
invasion. A further 6 were classified as adenocarcinomas, 3 as adenosquamous 
carcinomas and 1 as an undifferentiated carcinoma. In 8 patients the histopathology 
results were not available. 
3.2. Preparation of biopsy DNA 
3.2 . 1. DNA Extraction 
Just prior to processing, the biopsies were thawed and a small amount of ground 
glass was added to each biopsy. The biopsies were ground in a mortar and pestle 
and suspended in 4ml of lysis buffer containing lOOmM Tris, lOOmM NaCl, 5mM 
EDTA (pH 7,5) and 1 % SDS w/v and transferred to a conical polypropylene tube. 
(Falcon, New Jersey, USA). (Crum et al., 1985). Proteinase K (Boehringer-
Mannheim, FRG) was added to a final concentration of 100 ug/ml of the mixture 
which then was incubated for at least 3 hours at 560c. The DNA was extracted 
twice with phenol. One milliliter of ultrapure water (BDH Ltd., England) was 
added to the interface of the first extraction which was re-extracted with phenol, 
and the aqueous phases were pooled prior to the second phenol extraction. 
(Williamson et al., 1989). The DNA was then extracted once with chloroform: 
isoamyl alcohol (24: 1). After the chloroform extraction the aqueous phase 
containing the DNA was transferred into microfuge tubes (Eppendorf, FRG) and 
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3M CH3COONa was added to a final concentration of 0,3M CH3COONa. Two 
volumes of 100 % ethanol were added and the microfuge tubes were placed on dry 
ice for 15 minutes. The DNA was recovered by centrifugation in a Sigma 201M 
microfuge at 10 000 rpm for 15 minutes. The pellets were washed with 500ul of 
70% alcohol , centrifuged at 10 OOOrpm for 15 minutes, dried in a dessicator, 
resuspended in 10 ul of ultra-pure water and stored at 40c. 
3.2.2. Estimation of the amount of DNA 
Ten microliters of each sample of biopsy DNA was subjected to electrophoresis in a 
1 % agarose gel at 80 volts for. 1 hour. A Hind III digest of 1 ug of lambda phage 
DNA was included in each gel. The gel was then stained with ethidium bromide at 
a concentration of 0,5ug/ml of water and viewed on an ultraviolet transilluminator. 
The bands of DNA in each lane were visually evaluated. (Berger and Kimmel , 
1987). 
3.3. Restriction endonuclease digestion and agarose gel 
electrophoresis 
Four to eight micrograms of biopsy DNA were utilised in each reaction. One unit 
of the restriction enzyme Pstl together with the appropriate buffer (Boehringer 
Mannheim, FRG) was added for each estimated microgram of sample DNA. 
Reaction mixtures were incubated for 1 hour at 370c prior to termination with 
lOOmM NaEDTA (ph 8), 1 % SDS, 0,1 % bromophenol blue and 0,1 % xylene 
cyanol. 
One per cent agarose (SeaKem, FMC Bioproducts, USA) was dissolved in Tris-
acetate buffer (0,04M Tris-acetate and 0,001M EDTA). and poured at 560c into 
appropriately sized molds. The gels were placed in submarine electrophoresis tanks 
with Tris-acetate buffer. Samples digested with Pstl were loaded into each well. 
lambda DNA digested with Pstl was loaded into the first and last well. The DNA 
fragments were separated at a constant voltage of 80 volts for 4 hours or overnight 
at 30 volts. 
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Gels were stained with the fluorescent dye, ethidium bromide, at a concentration of 
0,5ug/ml of water and visualized on an ultraviolet transilluminator. (Maniatis, 
1982). 
3.4. Photography 
After staining with ethidium bromide the agarose gel was photographed on an 
ultraviolet transilluminator. Two photographs were taken, one with a ruler aligned 
vertically and one with a ruler aligned horizontally to facilitate later interpretation 
of fragment size. 
3.5. Comparison of methods used for transfer of DNA fragments 
In order to optimize transfer of DNA fragments onto a nylon membrane, (Hybond 
N + , Amersham, UK) , an experiment comparing Smith and Summers Southern 
blotting with classical Southern blotting and electroblotting was performed. Plasmid 
(pBR 322) DNA containing cloned HPV 16 DNA was quantitated using the method 
described for biopsy DNA and digested with the restriction endonuclease Pstl.. 
Serial tenfold dilutions from lug to 1 pg of the digested cloned HPV 16 DNA were 
made. Equivalent amounts of DNA were subjected to electrophoresis on three 1 % 
agarose gels. The following methods of DNA transfer to a nylon membrane were 
compared: 
3.5.1. Smith and Summers Southern blotting 
After electrophoresis one of the agarose gels was placed in 0,25M HCl and gently 
agitated for 20 minutes. The gel was then rinsed in distilled water and placed in 
0,5M NaOH and 1,5M NaCl for 20 minutes to denature the DNA fragments. After 
rinsing, the gel was neutralized in lM CH3COOHNH4 and 0,02M NaOH for 40 
minutes. The agarose gel was then placed onto a solid surface. A nylon membrane 
exactly the size of the gel was placed on top of the gel. Care was taken to avoid 
trapping bubbles beneath the membrane. Three sheets of Whatman 3mm filter 
paper were placed on top of the nylon membrane and a stack of paper towels was 
placed on top of the filter paper. The filter paper and stack of paper towels were 
weighted to ensure even transfer of the DNA fragments. 
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3.5.2. Classical Southern blotting: 
After electrophoresis a second agarose gel was placed in 0.25M HCI for 20 
minutes. The gel was then rinsed in distilJed· water and a tray with a platform 
covered with a wick made from 3 sheets of Whatman 3MM filter paper was filled 
with 0,4M NaOH. The agarose gel was placed on the wick and a sheet of the 
nylon membrane exactly the size of the gel was placed on top of the gel. Care was 
taken to avoid trapping bubbles beneath the membrane. Three sheets of Whatman 
3MM filter paper, a stack of absorbent paper towels and weights were placed on 
top of the nylon membrane. Transfer was allowed to proceed over night. 
3.5.3. Electroblotting 
After electrophoresis DNA in the third agarose gel was denatured and neutralized 
as described for the Southern blotting procedure. The agarose gel was then placed 
in 25mM Tris, pH 7.4 for 10 minutes. A sponge saturated with 25mM Tris and 
piece of blotting paper were placed on top of a graphite anode. The nylon 
membrane was placed on top of the blotting paper, followed by the agarose gel, 
another piece of blotting paper and a second sponge saturated with 25mM Tris. A 
graphite cathode was placed on top of the sponge. Electrophoretic transfer was then 
allowed to proceed over 4 hours at a constant voltage of 100 volts. (Rybicki -
personal communication). 
The DNA fragments on all three of the nylon membranes were fixed by placing 
each membrane on two to three pieces of blotting paper soaked in 0,4M NaOH for 
twenty minutes. 
3.6. Standardization of conditions used to suppress background 
radioactivity 
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An experiment was performed to determine the optimal conditions for 
prehybridization. Dilutions of cloned HPV 16 were made as described above. Two 
prehybridization solutions were compared: 
1. The nylon membranes were prehybridized overnight in 6xSSC (0,9M 
NaCl and 0,9M sodium citrate), 30% formamide v/v, 0.02% salmon sperm 
w/v (Sigma, St. Louis) and 0,5 % w/v fat-free milk powder at 420c 
(Williamson et al, 1989). 
2. The nylon membranes were prehybridized in a 5 % solution of 
commercial blocking reagent w/v (Boehringer Mannheim, FRG) dissolved 
in 6xSSC with 30% formamide v/v and 10% Dextran Sulphate w/v at 420c 
overnight. Samples were processed using this method. 
3.7. Plasmids 
Plasmids containing cloned HPV 16 and 18 DNA were provided by Dr E-M de 
Villiers (German Cancer Research Centre, Heidelberg, FRG), plasmid containing 
HPV 31 and 35 were provided by Dr A. T. Lorincz (Bethesda Research 
Laboratories, Gaithersberg) and plasmid containing HPV 33 was provided by Dr. 
G. Orth (Pasteur Institute, Paris). 
3.7.1. Transformation of competent (DK-1) cells with HPV DNA 
Competent cells (DK-1 cells, an E. Coli strain) were kindly prepared by Karen 
Pratt in the Molecular Biology Unit, Department of Medical Microbiology, 
University of Cape Town. 
Ten microliters of each HPV plasmid, containing less than 40ng of DNA was used. 
The amount of plasmid DNA was calculated from the concentration value supplied 
by the laboratory donating the plasmid. This was added to 200ul of DK-1 cells with 
a transforming efficiency of 5x106 transformants per microgram of DNA. The 
mixture was placed on ice for 30 minutes. The tubes were then transferred to a 
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water-bath and heat shocked for 2 minutes at 420c. One milliliter of Luria broth 
was added to each tube and the mixture was incubated for 1 - 3 hours. Two 
hundred microliters of this transformation mixture was spread onto Luria agar 
plates containing ampicillin. The plates were allowed to dry and then inverted and 
incubated at 370c overnight. 
The following day a single colony was selected and inoculated into 5 ml of Luria 
broth and incubated overnight. (Maniatis, 1982). 
3.7.2. Plasmid mini-preparations 
Three milliliters of the above E. Coli culture was centrifuged in microfuge tubes. 
A minipreparation kit (Diagen, FRG) was used according to the manufacturers 
instructions. Briefly, the bacterial pellet was resuspended in a buffer containing 
RNase A (100 mg/ml) in 50mM Tris/HCl and lOmM EDTA, pH 8. Three hundred 
microliters of a second buffer containing 200mM NaOH and 0, 1 % SDS w/v was 
added and the mixture was incubated at room temperature for five minutes. Three 
hundred microliters of a third buffer containing 2,55M CH3COOK was then added, 
the solution was mixed gently and centrifuged in microfuge tubes for 15 minutes. 
The supernatant was removed. An anion exchange resin (Quigen mini-column, 
Diagen, FRG) was equilibrated with 1 ml of a buffer containing 750mM NaCl, 
50mM MOPS (3-N-morpholino-propanesulphonic acid) and 15% ethanol v/v, pH 
7. · The supernatant containing the plasmid DNA was adde4 to the column. 
Impurities were eluted from the column using a buffer containing 1,0M NaCl, 
50mM MOPS and 15% ethanol v/v, pH 7.0. The plasmid DNA was eluted with a 
buffer containing 1,2M NaCl, 50mM MOPS and 15 % ethanol, pH 8. 
The plasmid DNA was precipitated as described for the processing of the biopsy 
DNA and dissolved in 50ul of TE buffer (lOmM Tris/HCl and lmM EDTA). 
Ten microliters of the plasmid DNA solution were digested with the restriction 
endonuclease Pstl. The plasmid DNA fragments together with a known quantity of 
a DNA molecular weight marker (lambda phage DNA digested with the restriction 
endomiclease Pstl) were separated by electrophoresis on a 1 % agarose gel. The 
agarose gel was stained with ethidium bromide at a concentration of 0,5ug/ml of 
water and viewed on an ultraviolet transilluminator. The size of the fragments 
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obtained after digestion of the plasmid DNA and separation of the fragments by 
electrophoresis was determined. 
3.8. Preparation of the HPV DNA probe. 
3.8.1. Preparation of HPV specific fragments 
HPV 16 plasmid DNA was incubated with the appropriate volume of the restriction 
enzymeBam HI and restriction buffer to excise the HPV specific fragment. Plasmid 
DNA and the HPV 16 specific fragment were separated by electrophoresis at a 
constant voltage of 80 volts for 1 hour. The piece of agarose gel containing the 
HPV fragment was excised, cut into fine pieces and extracted twice with phenol 
and once with chloroform-isoamyl alcohol (24: 1). The DNA was recovered by 
ethanol salt precipitation. HPV DNA fragments were prepared in the same way for 
HPV types 18, 31, 33 and 35 using the appropriate restriction endonuclease to 
excise the HPV specific fragment. (BamHI for HPV 35, EcoRI for HPV 18 and 31 
and Bgffi for HPV 33). The concentration of the HPV specific fragment was 
estimated using the method described above for quantitation of biopsy DNA. 
3.8.2. 32p Labeling 
The HPV DNA specific fragments were labelled with 32p by random priming. 
(Multiprime DNA labeling system, Amersham, U.K.) The kit was used according 
to the manufacturers instructions. Twenty-five nanograms of the appropriate HPV 
specific DNA fragment was denatured by heating to 95 - 1000c for 2 minutes and 
then chilled on ice. Ten microliters of a buffer supplied by the manufacturers 
containing unlabeled nucleotides (dATP, dTTP and dGTP) was added to the DNA 
solution followed by 5 ul of a solution containing random sequence hexamers. The 
volume was adjusted to 50ul by the addition of deionized water. Five microliters of 
radiolabelled (32p) nucleotide (dCTP) and 2ul DNA polymerase were then added. 
The reaction was then incubated at room temperature for at least 3 hours. 
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3.8.3. Removal of unincorporated label by Sephadex G-50 chromotography 
The reaction mixture was layered onto the surface a column of Sephadex G-50. 
(Pharmacia, Sweden). Fractions of 80ul were eluted from the column using a 
buffer containing 150mM NaCl, lOmM EDTA, 0, 1 % SDS (w/v) and 50mM Tris. 
The radioactivity of the eluted fractions was determined using a hand-held Geiger 
counter and the fractions containing labelled DNA were pooled. The DNA was then 
denatured by heating. (Maniatis, 1982). 
3.9. Hybridization and posthybridization washes. 
The pooled radiolabelled probe was added to the prehybridization buffer and 
hybridized to the biopsy DNA bound to the nylon membrane for 24 - 48 hours at 
420c. 
Unbound radiolabelled HPV prob~ was removed from the nylon membrane by 1 
wash of 2xSSC with 0, 1 % SDS w/v followed by 2 washes of 0,5xSSC with 0, 1 % 
SDS w/v at room temperature. 
3.10. Autoradiography and estimation of DNA fragment size 
The nylon membranes were wrapped in a plastic folder and placed on a piece of X-
ray film (Curix RPI, Bayer, South Africa) in an X-ray cassette with two image 
intensifying screens. This was stored at -7o0c for 1 - 3 weeks. The X-ray films 
were developed using Ilford Phenisol x-ray developer and fixed with Amfix high 
speed fixer (Maybaker, Port Elizabeth). 
The distance travelled by the DNA fragments detected by hybridization was 
measured and the molecular weight was calculated using a computer programme 
"Gel". 
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3.11. The Polymerase Chain Reaction for the detection of HPV 16 
The polymerase chain reaction was performed using a DNA amplification reagent 
kit (GeneAmp, Perkin Elmer Cetus, Norwalk, USA) according to the 
manufacturers instructions. Great care was taken to avoid DNA contamination. 
Reactions were performed in capped 0,5ml polypropylene microfuge tubes. A 
clinical specimen in which HPV 16 had been detected with Southern blot 
hybridization was used as a positive control. 
Primers with the following sequences were used for PCR: 
Primer 1 5'AGGCCAACTAAATGTCAC (Tidy et al., 1989) 
Primer 2 5'GGTGCATAAAATGTCTGC (A-L Williamson - personal 
communication from Seedorf et al., 1985) 
A mixture of the polymerase chain reaction components was made containing 0,6ug 
of each primer (2ul of each primer) and 0,2mM (lul) each the nucleotide solutions 
dATP, dGTP, dCTP and dTTP supplied by the manufacturer per reaction. Reaction 
buffer containing a final concentration of lOmM Tris-HCl, 50mM KCl, 1,5mM 
MgCI2 and 0,001 % gelatin w/v was added. A recombinant Taq DNA polymerase 
"Amplitaq" (Perkin Elmer Cetus, Norwalk, USA) was used at a concentration of 
2,5 units/assay. Biopsy DNA (0,6ug) was added and the final volume was adjusted 
to 50ul/reaction with distilled water. 
A thermal cycler (Techne PHC-2) was used. The DNA was first denatured at 940c 
for 4 minutes. This was followed by 35 cycles of denaturation (1 minute at 940c), 
annealing (2 minutes at 450c) and extension (3 minutes at 720c). After completion 
of the 35th cycle of amplification , extension was completed at 720c for 7 minutes. 
Fifteen microliters of the amplified reaction mix was then subjected to 
electrophoresis on a 3 % agarose gel together with molecular weight markers (DNA 
molecular weight marker Vl - Boehringer Mannheim, FRG). Ethidium bromide 
was incorporated into the gel at a final concentration of 0,5ug/ml. The distance 
travelled by the amplified PCR product was compared to the distance travelled by 
the molecular weight marker. 
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To confirm the specificity of the amplified product, the DNA fragments were 
transferred onto a nylon membrane (Hybond N +, Amersham, UK) using the Smith 
and Summers modification of Southern blotting and treated with a commercial 
blocking reagent (Boehringer Mannheim, FRG) dissolved in 6XSSC with 30% 
formamide v/v at 420c overnight. 
A HPV type 16 probe consisting of amplified plasmid was labelled with 
32P.(Multiprime DNA labeling system, Amersham, UK). Preparation of the DNA 
probe, hybridisation, post-hybridisation washes and autoradiography were 
performed as described above. 
4. Results 
4.1. Determination of optimal conditions for transfer of DNA 
fragments to a nylon membrane 
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The lowest dilution of plasmid detected usmg electroblotting and Smith and 
Summers Southern blotting was lng compared to lOng for classical Southern 
blotting. 
4.2. Standardization of conditions used to suppress background 
radioactivity 
The result of pre-treating nylon membranes a prehybridization solution containing a 
5 % solution of a commercial blocking agent (Boehringer Mannheim, FRG) 
dissolved in 6xSSC with 30% formamide v/v and 10% Dextran sulphate w/v is 
shown in figure 9a. There is a marked reduction in background radioactivity when 
compared to the nylon membrane treated with a prehybridization solution 
containing 6xSSC, 30% formamide, 0.02% salmon sperm w/v and 0,5% v/w fat-
free milk powder. (figure 9b). 
4.3. Southern blot hybridization 
A total of 86/93 biopsies were processed by the method described using the Smith 
and Summers modification of Southern blotting. Each specimen was probed with 
cloned HPV types 16, 18, 31, 33 and 35. (See table 1). Autoradiographs with no 
detectable HPV DNA after 3 weeks were considered to be negative. 
4.3.1. HPV 16 probe. 
A typical pattern was seen in 13/86 of the biopsies after digestion with the 
restriction endonuclease Pstl. This pattern is illustrated in lane 3 of figure 4 and 
lanes 1 and 2 of figure 5b. Biopsy DNA from a further 3 cases (cases 7, 27 and 91) 
hybridized with the cloned HPV 16 probe, however the pattern obtained differed 
from that of the typical HPV 16 pattern. (See figure 4, lane 1). 
32 
4.3.2. HPV 18 probe 
Two out of a total of 86 biopsies showed a typical pattern with the HPV 18 probe. 
(See table 1). Figure 7 shows a photograph of an autoradiograph with biopsy DNA 
digested with Pstl. Two fragments of 6337 bp and 555 bp are visible. 
4.3.3. HPV 31 probe 
Biopsy DNA from patient 73, a 44 year old coloured women showed a pattern 
consistent with HPV 31. 
4.3.4. HPV 33 probe 
Biopsy DNA from 1 patient hybridized with a cloned HPV 33 probe with a pattern 
consistent with HPV 33. 
4.3.5. HPV 35 probe 
No hybridization consistent with the pattern of HPV 35 was obtained after Pstl 
digestion of biopsy DNA 
4.3.6. Unclassified patterns 
In 18/86 patients the biopsy DNA obtained cross-hybridized with one or more of 
the cloned HPV DNA probes but the pattern obtained was variable. Biopsy DNA 
from 11 patients cross-hybridized with the cloned HPV 16 probe, 3 cross-
hybridized with the HPV 33 probe and 1 with the HPV 31 probe. A further 3 
biopsies cross- hybridized with a combination of HPV DNA probes - 1 with HPV 
16 and 31, 1 with HPV 16 and 18 and 1 with HPV 16 and 35. Lane 10 of figure 6 
shows biopsy DNA from patient 14 cross-hybridizing with the HPV 33 probe. 
Biopsy DNA which did not hybridize with any of the probes used was further 
investigated for the presence of HPV 16 DNA using the polymerase chain reaction. 
Another 7 biopsies with insufficient DNA for processing by Southern blot 
hybridization were also investigated using this technique. 
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Figure 8 shows the detection of a 229bp amplified fragment with a PCR generated 
HPV 16 fragment labelled with 32p. The positive control (lane 2) was biopsy DNA 
from one of the patients with carcinoma of the cervix in which HPV 16 was 
detected by Southern blot hybridization. In lanes 8, 11 and 13 samples containing 
amplified DNA hybridizing with the HPV 16 probe can be seen. The signal in lane 
11 is extremely faint, but became clearer after the autoradiograph was exposed for 
a longer time. In some of the specimens a lower molecular weight product cross-
hybridized with the probe. (lane 17) This was thought to be an artifact caused by 
primer oligomerization. Amplification of the 229 bp fragment which hybridized 
with a HPV 16 probe was obtained in 3/48 biopsies with no detectable HPV DNA 
by Southern blot hybridization and in 2/7 of the biopsies with insufficient DNA for 
Southern blot hybridization. 
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Table 1 
Detection of HPV 16, 18, 31, 33 and 35 in patients with invasive 
carcinoma of the cervix in Cape Town 
Patient Age Race Histopath HPV HPV16 Comment 
No. 
Probe PCR 
1 60 Black Squamous HPV 16 
2 42 Black Squamous Unclass. 
3 44 Black Squamous 
4 50 Coloured Squamous HPV33 
5 77 Black Squamous HPV 16 Extra 
bands 
6 46 Coloured Squamous 
7 42 Black Adeno-sq HPV 16 Extra 
variant bands 
8 66 Black Adenoca 
9 76 Coloured Squamous HPV 16 
10 73 White Squamous 
11 68 Black Squamous 
12 38 Coloured Squamous 
13 78 Coloured Squamous Unclass. 
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Patient Age Race Histopath HPV HPV 16 Comment 
No. 
Probe PCR 
14 35 Black Undiff. Unclass. 
15 63 Black Squamous HPV 16 
16 50 Coloured Squamous 
17 56 Coloured Squamous Unclass. 
18 63 White Squamous HPV 16 
19 67 Coloured Squamous 
20 60 Coloured Squamous 
21 45 Black Squamous 
22 40 Black Squamous HPV 16 
23 29 Coloured Adeno HPV 18 
24 41 Black Squamous 
25 66 White Squamous · HPV 16 Extra 
bands 
26 44 White Squamous 
27 56 Coloured Squamous HPV16 
variant 
28 46 Coloured Squamous HPV 16 Extra 
bands 
29 41 Coloured Squamous 
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Patient Age Race Histopath HPV HPV 16 Comment 
No. 
Probe PCR 
30 47 Coloured Adenoca 
31 66 Coloured Squamous Unclass. 
32 54 Coloured Squamous 
33 50 Black Squamous 
34 36 Coloured Adeno-sq HPV 16 Extra 
bands 
35 55 Black Squamous Unclass. 
36 57 Coloured Squamous 
37 28 Coloured Squamous Unclass. 
38 34 Coloured Squamous 
39 34 Coloured Squamous 
40 47 Coloured Squamous Unclass. 
41 42 Black Squamous 
42 42 Coloured Squamous 
43 77 Coloured Squamous 
44 68 White Squamous Unclass. 
45 50 Black Adenoca 
46 30 Black Adenoca 
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Patient Age Race Histopath HPV HPV16 Comment 
No. 
Probe PCR 
47 42 Black Squamous 
48 69 Coloured Squamous Unclass. 
49 60 Black Squamous 
50 57 Coloured Squamous 
51 52 Coloured Not Unclass. 
available 
52 28 White Squamous Unclass. 
53 50 Black Squamous 
54 27 Black Squamous HPV 18 
55 44 Coloured Squamous HPV 16 Extra 
bands 
56 57 Coloured Squamous 
57 58 Coloured Squamous 
58 59 Black Adeno-sq Unclass. 
59 43 Black Squamous Unclass. 
60 56 White Squamous Unclass. 
61 53 Coloured Squamous 
62 35 Black Squamous 
63 30 Black Squamous Unclass. 
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Patient Age Race Histopath HPV HPV16 Comment 
No. 
Probe PCR 
64 40 Black . Squamous 
65 54 Black Squamous HPV 16 
66 48 Coloured Squamous 
67 51 Coloured Squamous HPV 16 
68 56 Coloured Squamous 
69 39 Coloured Adenoca 
70 57 Black Adenoca 
71 53 Coloured Squamous 
72 48 Black Squamous 
73 44 Coloured Squamous . HPV31 
74 48 Black Squamous Unclass. 
75 58 Coloured Squamous 
76 55 Coloured Squamous HPV 16 
77 48 Black Squamous 
78 58 Black Squamous 
79 53 Black Squamous 
80 48 Coloured Squamous HPV 16 
81 43 Coloured Squamous 
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Patient Age Race Histopath HPV HPV 16 Comment 
No. 
Probe PCR 
82 52 Coloured Squamous HPV 16 
83 38 Coloured Not 
available 
84 67 Coloured Squamous 
85 NIA NIA Not Unclass. 
available . 
86 NIA NIA Not 
available 
87 42 Coloured Squamous HPV 16 
88 44 Coloured Squamous 
89 31 Coloured Squamous HPV 16 Extra 
bands 
90 NIA NIA Not 
available 
91 NIA NIA Not HPV 16 
available variant 
92 NIA NIA Not 
available 




5.1. Quantitation of biopsy DNA. 
The quantity of DNA recovered from each biopsy was estimated by the intensity of 
the ethidium bromide staining when compared to a known amount of Hind III 
digested lambda DNA fragments subjected to electrophoresis in the same 1 % 
agarose gel. This method provides a crude estimation of the amount of DNA 
obtained from each biopsy. Shearing of DNA that inevitably occurs during 
preparation allows the biopsy DNA to migrate into the 1 % agarose gel and enables 
rough quantitation of the biopsy DNA. 
5.2. Determination of the optimal conditions for transfer of DNA 
fragments to the nylon membrane. 
There was a tenfold reduction of sensitivity when classical Southern blotting was 
compared to Smith and Summers Southern blotting and electroblotting. As transfer 
of DNA fragments appeared to be less efficient in classical Southern blotting, it 
was decided to use the Smith and Summers modification of Southern blotting to 
process the clinical specimens. 
5.3. Optimization of conditions to suppress background 
radioactivity 
This experiment clearly demonstrated that a 5 % solution of a commercial blocking 
agent (Boehringer Mannheim, FRG) allowed adequate detection of the HPV 
specific fragments with minimal non-specific binding of 32p to the nylon 
membrane. (See figure 9). 
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5.4. Classification of HPV types by Southern blot hybridization 
The HPV types were classified by the Pstl fragment lengths. (see appendix). The 
Pstl fragment sizes were calculated using the computer programme "Gel" by 
measuring the distance travelled by the HPV DNA fragment and comparing this to 
the distance travelled by the molecular weight marker. This method utilizes the fact 
that the reciprocal of the mobility plotted against fragment length is linear. A least 
square analysis is used. (Schaffer and Sederoff, 1981). 
A variety of Pstl fragments may be observed in the autoradiograph demonstrated in 
figure 4. The HPV 16 pattern is demonstrated in lane 3. The pattern observed 
correlates with the fragments obtained from Pstl digestion of HPV 16. (Baker, 
1987). In lane 1 of figure 4 is a possible variant of HPV 16. Fragment A is slightly 
smaller (2700 bp) when compared to the HPV 16 prototype fragment of 2800 bp 
and fragment D was slightly larger (1200 bp) than the HPV 16 prototype fragment 
of 1000 bp. Fragments B and C were identical in size to the HPV 16 prototype 
fragments. Interestingly 3 % of the biopsies investigated by Southern blot contained 
this HPV 16 "vatiant". 
In figure 6 a PstI digest of biopsy DNA conforming with the HPV 33 prototype can 
be seen in lane 1. (see appendix). Biopsy DNA in lanes 2, 4 and 6 contain HPV 16 
cross-hybridizing with the cloned HPV 33 probe. (see below). 
HPV 18 DNA was detected in biopsies obtained from 2 patients. Figure 7 shows 
the detection of HPV 18 in a 29 year old female with an adenocarcinoma of the 
cervix. The presence of HPV 18 was further confirmed by the sequencing of a PCR 
generated fragment by Susan Dennis from the Department of Microbiology, 
University·of Cape Town. (Williamson - personal communication). 
Twenty-one per cent ( 18/86) of biopsies from patients with invasive carcinoma of 
the cervix contained "unclassified" HPV DNA. Biopsy DNA from these patients 
cross-hybridized with one, or more of the cloned HPV DNA probes but the patterns 
obtained did not match that of HPV types 16, 18, 31, 33 or 35. Most of these 
(11/18) biopsies cross-hybridized with the HPV 16 probe, 3 cross-hybridized with 
the HPV 33 probe and 1 with HPV 31 probe. A further 3 biopsies cross-hybridized 
with more than one of the HPV DNA probes - 1 with HPV 16 and 31, 1 with HPV 
42 
16 and 18 and 1 with HPV 16 and 35. Most of the unclassified types appeared to be 
distinct from each other. Figure 5a shows a biopsy containing an unclassified HPV 
type. In this example the biopsy hybridized with cloned HPV 16 under conditions 
of moderate stringency, generating 2 fragments of 2818 bp and 1776 bp 
respectively. These are identical to the molecular weights of fragments A and B of 
the HPV 16 prototype. Although this biopsy was included as an unclassified HPV 
type, it could possibly be an integrated form of HPV 16 (see below) . Another 
unclassified HPV type is demonstrated in lane 10 of figure 6. The biopsy DNA 
cross-hybridized with 'the cloned HPV 33 probe generating a single fragment. 
Table 2 summarizes the HPV types detected in this study. 
HPV PROBE 
HPV 16 







HPV !l'.n§ in biopsies obtained from 86 patients 
with carcinoma of the cervix detected by 
Southern blot hybridization 


















HPV 16 was detected in only 15% of biopsies obtained from patients with invasive 
carcinoma of the cervix in Cape Town. This is somewhat lower than many of the 
studies. However, comparison with a study by Williamson et al., 1989 on the 
molecular typing in patients with CIN 3 in Cape Town showed a similar detection 
rate of HPV infection, although significantly less HPV type 33 was detected in 
patients with carcinoma of the cervix in Cape Town. (Williamson et al., 1989) 
The number of unclassified HPV types detected in patients with carcinoma of the 
cervix was also lower. (see Table 4 below) 
Table 4 
Comparison of the prevalence of HPV infection in biopsies obtained 
from patients with CIN 3 and invasive carcinoma of the cervix 
in Cape Town. 
HPV Type Number positive(%) 
CIN 3* Carcinoma of the cervix 
HPV type 16 16/98 (16%) 13/86 (15%) 
HPV type 16 "variant" 6/98 (6%) 3/86 (4%) 
HPV type 18 1/98 (1 %) 2/86 (2%) 
HPV type 31 2/98 (2%) 1/86 (1 %) 
HPV type 33 8/98 (8%) 1/86 (1 %) 
HPV35 0/98 0/86 
Unclassified 35/98 (36%) 18/86 (21 %) 
TOTAL 68/98 (69%) 38/86 (44%) 
*Williamson et al., 1989 
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5.6. Sensitivity of detection of HPV DNA. 
The lower prevalence of HPV 16 in our patients with genital malignancies was of 
some concern to us. The study from Germany by Durst et al., 1983 showed that 
61 % of patients with invasive carcinoma of the cervix had HPV 16 DNA detected 
by Southern blot hybridization. (Durst et al., 1983). Although Fukushima et al., 
1985 showed that only 11 % of biopsies from patients with invasive squamous 
carcinoma of the cervix contained HPV 16 DNA, their study was numerically small 
consisting of a total of 11 patients. (Fukushima et al., 1985). Other studies reported 
40% or more of biopsies containing HPV 16 DNA. (Durst et al., 1983; McCance 
et al., 1985 and Choo et al., 1987). 
Of importance, however, was the fact that the study by Williamson et al., 1989, on 
the molecular typing of HPV in patients with cervical intraepithelial neoplasia grade 
3 in Cape Town showed a similar detection rate of HPV infection using HPV 16, 
18, 31, 33 and 35 probes, although significantly less HPV 33 was detected in 
patients with carcinoma of the cervix in Cape Town. (Williamson et al., 1989). 
This similarity in the prevalence of HPV infection in patients with CIN 3 and 
carcinoma of the cervix in Cape Town suggest a truly low prevalence of HPV 16, 
18, 31, 33 and 35 in this region. 
This low prevalence was further substantiated by the use of the polymerase chain 
reaction for the detection of HPV 16 in biopsies from patients in this study who had 
no detectable HPV DNA on Southern blot hybridization, or where there was 
insufficient DNA for Southern blot hybridization. The primers used were designed 
for selective DNA amplification of the upstream regulatory region, as this region 
together with the E6 and E7 regions are almost always retained when HPV DNA 
integrates in malignant tumours. (Tidy et al., 1989b). Three of the biopsies with no 
detectable HPV DNA on Southern blot hybridization contained HPV 16 DNA using 
the polymerase chain reaction. Assuming that in all the samples with detectable 
HPV 16 DNA by Southern blot hybridization selective DNA amplification of HPV 
16 would also be possible, the use of the polymerase chain reaction has enhanced 
the sensitivity to a total of 16/86 (19%) containing HPV 16 DNA. This also 
assumes that no mixed infection existed in the other biopsies with detectable HPV 
DNA. In a further two biopsies in which selective DNA amplification of HPV 16 
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was achieved, using the polymerase chain reaction, the amount of DNA for 
detection using Southern blotting was judged to be insufficient. 
The results obtained from the use of the polymerase chain reaction in this study, 
together with the similarity of the results obtained by Williamson et al., 1989 in 
their study on cervical intraepithelial neoplasia in Cape Town, indicate that the low 
prevalence of HPV 16 in this region is not due to an inadequate detection system by 
Southern blot hybridization. 
The polymerase chain reaction is theoretically capable of detecting a single virus 
genome in 1o5 cells. It is therefore at least lo5 fold more sensitive than Southern 
blotting which is capable of detecting one copy of viral DNA per cell. (Young et 
al., 1989). The exquisite sensitivity of this technique is also one of it's major 
drawbacks. Great care must be taken to avoid contamination of samples with 
subsequent false positive results. (Tidy et al., 1989c). Contamination ·did not occur 
in this study. No amplification was observed in the negative controls containing no 
DNA. In addition the biopsies in which selective DNA amplification occurred were 
evenly distributed throughout the study. 
5.7. Typing of human papillomaviruses in carcinoma of the cervix 
An ever-increasing number of different human papillomavirus types are being 
described in association with carcinoma of the cervix. (Durst et al., 1983; Boshart 
et al., 1984; Beaudenon et al., 1986). A total of 24 different HPV types have been 
detected in the genital tract. (De Villiers et al., 1989 ). In this study only 5 of these 
types were sought using homologous cloned HPV DNA probes. 
HPV 16 ~as the first HPV type to be described in association with carcinoma of 
the cervix and many studies to date have reported the prevalence of HPV 16. 
(Durst et al., 1983; Mccance et al., 1985; Choo et al., 1987 and Fukushima et 
al., 1985). However, in this study most of the biopsies in which HPV DNA was 
detected contained "unclassified" HPV DNA. Interestingly the study by Williamson 
et al., 1989 also demonstrated a significant proportion of "unclassified" HPV types 
(35/98 - 36% ). These could represent new HPV types and further characterization 
may reveal novel HPV types of importance in the development of cervical 
neoplasia in this geographical region. 
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These "unclassified" HPV types highlight some of the difficulties experienced in 
classifying HPV types in biopsies obtained from patients with malignancy of the 
cervix. These difficulties may be due to: 
5.7.1. Integration of the viral DNA into the host cell chromosome. 
If integration of the HPV DNA into the host cell chromosome occurs, 
interpretation of the results obtained by Southern blot analysis is difficult. 
This difficulty is illustrated in figure 5a which shows biopsy DNA 
hybridizing strongly with the 2818 bp and 1776 bp fragments of a cloned 
HPV 16 probe. This could possibly represent the integration of part of the 
HPV 16 genome with interruption of some of the HPV genes so that certain 
Pstl fragments usually generated by the digestion of episomal HPV DNA 
are lost. 
5.7.2. 2.Cross-hybridization of non-homologous HPV probes. 
The cross-hybridization by related HPV strains with a non-homologous 
probe may result in a variation in the intensity of the bands generated after 
restriction endonuclease digestion, Southern blot hybridization and detection 
with a 32p labelled cloned HPV probe. Individual bands may not be of 
sufficient homology to allow detection by this method. Definitive 
identification of related strains using a non-homologous probe is therefore 
extremely difficult. This is illustrated in figure 6. Lane 1 shows an HPV 33 
prototype. In lanes 4 and 6 strong cross- hybridization with the HPV 33 
probe can be seen with fragments A and C of HPV 16. Fragment A of HPV 
16 contains part of the Ela ORF, the Elb ORF, the E2 ORF and the E4 
ORF. (see appendix). The El ORF proteins are highly conserved over the 
COOR-terminal but less conserved over the NH2 terminal portion. (Balcer, 
1987). The E2 proteins are strongly homologous in the NH2 and COOH 
terminal domains. (Balcer, 1987). Homology between the El and E2 
sequences probably permit the strong cross-hybridization seen in fragment 
A. Fragment C of HPV 16 contains part of the LI ORF and part of the L2 
ORF. Although the Ll ORF encodes the major capsid protein of the 
papillomaviruses which is the most highly conserved of the papillomavirus 
proteins, the L2 proteins have been shown to be well conserved only at the 
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NH2 domain. Homology of the L2 proteins is probably responsible for the 
strong cross- hybridization of fragment C of HPV 16 with the cloned HPV 
33 probe. Fragment Band D of the Pstl digest of HPV 16 show less intense 
cross-hybridization with the HPV 33 probe. Fragment B contains the 
E6/E7/LCR and small portions of the Ll and Ela ORFs. Both the E6 and 
the E7 ORFs only show limited homology at the amino acid sequence level. 
(Baker, 1978). This would explain the less intense cross-hybridization. 
Fragment D contains the E4 and E5 ORF. The E4 proteins are only weakly 
homologous at the amino acid sequence level, possibly explaining the poorer 
cross- hybridization. (B~er, 1987). This highlights some the difficulties of 
typing HPV with non-homologous probes 
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5.8. The physical state of the viral DNA in the host cell 
Previous researchers have emphasized the importance of the physical state of the 
viral DNA within the host cell in the progression to malignancy. Durst et al., 1985 
showed that the viral DNA in biopsies obtained from patients with cervical cancer 
and in cell lines derived from cervical cancer cells is usually integrated into the host 
cell chromosome. (Durst et al. , 1985). This has been disputed by the findings of 
Matsukura et al. , 1989 who demonstrated that not only integrated, but also 
episomal HPV DNA alone can be demonstrated in patients with invasive carcinoma 
of the cervix. (Matsukura et al. , 1989). 
In our study we found the following: 
5.8.1. Integrated HPV DNA 
The unpredictable fragment size that may result from integration of HPV 
into the host cell chromosome makes interpretation of results obtained using 
Southern blot hybridization difficult as fragments normally generated by 
Pstl digestion of episomal HPV DNA are no longer present. This is 
illustrated in figure 5a which shows biopsy DNA cross-hybridizing with a 
cloned HPV 16 probe. The fragments of 2818bp and 1776bp correspond to 
fragments A and B of HPV 16 respectively. Fragment B contains the 
E6/E7 /LCR responsible for cell transformation by HPV. (Chen et al. , 
1982). There is a possibility that this biopsy contains an integrated HPV 
16, although it was included as an "unclassified" type. Similar findings were 
documented by Choo et al., 1987 who investigated biopsy material from 6 
patients with cancer of the cervix. The DNA samples were analyzed by Pstl 
cleavage. All of the 6 samples had distinct Pstl Southern blot patterns. Each 
biopsy had one or more of the HPV 16 prototype bands missing. The 1776 
bp fragment (fragment B) was, however, invariably retained in all of the 
biopsies. (Choo et al. , 1987). 
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5.8.2. Episomal HPV DNA 
HPV 16 DNA in an predominantly episomal form can be seen in lane 3 of 
figure 4. All of the fragments generated .from digestion with Pstl are clearly 
visible. No additional bands are visible. 
5.8.3. Combined episomal and integrated HPV DNA 
A possible combination of integrated and episomal HPV 16 is illustrated in 
lane 2 of figure 5b. The conventional fragments obtained after Pstl digestion 
are visible together with additional bands of 4000 bp and 3200bp 
respectively. Possible explanations for these additional bands include a 
partial digestion of the biopsy DNA by the restriction endonuclease, 
integration of the viral DNA into the host cell chromosome or a mixed 
infection with a combination of HPV 16 and a second HPV type. Analysis 
of the genetic map of HPV showed that a partial digest would not yield 
fragments with molecular weights the same as the additional bands seen in 
lane 2 of figure 5b. (see appendix) In addition fragment C (1549 bp) is far 
less intense than fragment B (1776 bp) despite the similarities of the 
molecular weights of these fragments. Fragment B contains the E6 and E7 
ORF together with the LCR. It has generally been accepted that integration 
is usually accompanied with the preferential retention of the E6/E7 /LCR 
region as E6 and E7 are important transforming genes of HPV. (Choo et 
al., 1987). The greater intensity of fragment B could therefore be explained 
by the localization of the E6/E7LCR in this region. This feature together 
with the presence of additional bands strongly suggests that this biopsy DNA 
contains both integrated and episomal HPV 16 DNA.The presence of both 
integrated and episomal DNA in biopsies from patients with invasive 
carcinoma of the cervix has also been demonstrated by Matsukura et al., 
1989. These investigators showed that 24/34 biopsies investigated had only 
episomal HPV 16 DNA, 8 had integrated HPV 16 DNA and 2 had a 
combination of integrated and episomal HPV DNA. (Matsukura et al., 
1989). 
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Another far less likely explanation for the additional bands present in this 
biopsy is a mixed infection of different HPV types with the additional bands 
representing a second type of HPV infection cross-hybridizing with the HPV 
16 probe under conditions of moderate stringency due to shared homology. 
Further investigation of the physical state of the viral DNA within the cell (that is 
whether the viral DNA is present in an episomal or integrated form) could include 
two-dimensional electrophoresis to separate linear and circular DNA, followed by 
Southern blotting and hybridization with a cloned HPV probe. The episomal HPV 
DNA is present in a circular form and the integrated HPV DNA is linear. (Durst et 
al., 1985). 
5.9. The prognostic significance detection of HPV DNA in biopsies 
from patients with invasive carcinoma of the cervix. 
Data obtained from the molecular typing of human papillomaviruses has enabled 
them to be classified into "high risk" types, for example HPV 16 and HPV 18, and 
"low risk" types, for example HPV 6 and 11. This division is not, however, 
absolute, as HPV 16 is not always associated with malignant lesions and has been 
demonstrated in a number of women whose prognosis is unknown. (Toon et al., 
1986). Although HPV 6 and 11 are classified as "low risk" viruses, they have 
occasionally been associated with malignant cervical disease. (Reeves et al., 
1987). It would, therefore be incorrect to believe that individuals infected with 
"low risk" HPV types have no risk of developing cervical cancer. 
Biopsies from 2 patients were shown to contain HPV 18 DNA (one of these 
patients had an adenocarcinoma of the cervix). Of interest was the fact that both of 
these patients were relatively young (29 and 27 years). In contrast to this the 
median age of patients with HPV 16 associated tumours in our study was 50 years. 
The clinical presentation and the course of the disease can vary greatly in patients 
with invasive carcinoma of the cervix. Some patients appear to have an unusually 
rapid progression of disease. A study by Barnes et al., 1988 evaluated the 
prognostic significance of HPV type 18 in biopsies from patients with invasive 
carcinoma of the cervix. They obtained biopsies from patients whose ages ranged 
from 27-80 years. Tumour histology among this group included squamous 
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carcinomas, adenosquamous carcinomas and adenocarcinomas. Comparison of the 
tumour grade with the HPV type showed that 4/6 HPV 18 associated tumours were 
poorly differentiated (one of these patients had an adenocarcinoma). In addition, the 
median age of the patients in their study with HPV 18 associated tumours was 37 
years, which was 12 years younger than the group of patients with HPV 16 
associated tumours. These observations suggest that HPV 18 may be associated 
with a more aggressive form of cervical neoplasia. (Barnes et al., 1988). Although 
biopsies from only two of our patients had detectable HPV 18 DNA, both of these 
patients were relatively young (29 and 27 years). One of these patients had an 
adenocarcinoma of the cervix. 
A further study on the role of HPV 18 in the development of cervical neoplasia 
postulated that HPV 18 might be involved in rapid progression of cervical 
intraepithelial neoplasia to invasive carcinoma of the cervix. Kurman et al., 1988 
documented a particularly low prevalence of HPV 18 infection in patients with all 
grades of cervical intraepithelial neoplasia. These authors showed that HPV 16 
accounted for 41 % and HPV 18 for 22 % of HPV infections in biopsies obtained 
from patients with invasive squamous carcinomas in their study. However, HPV 16 
was found in 37% of all grades of CIN but HPV 18 was present in only 3% of 
patients with CIN. This deficit of HPV 18 infection in CIN compared to cervical 
cancer could represent the rapid progression of HPV 18 through the intraepithelial 
stage of neoplasia. (Kurman et al., 1988). 
5.10. The role of HPV typing in South Africa 
South Africa has one of the highest incidences of cancer of the cervix in the world 
with an incidence of 0,6/1000 among black woman aged 15 - 65 years. (Cronje, 
1989). At this stage a full scale typing programme in South Africa is not indicated 
and preference should be given to cytological screening. In an editorial in the South 
African Medical Journal, Cronje points out that despite the high incidence of cancer 
of the cervix in South Africa cytological services have been abandoned in certain 
public health clinics due to lack of funds. He appeals for a nation- wide screening 
programme for cervical cancer using cervical cytology. (Cronje, 1989). Cervical 
cytology is an inexpensive and relatively effective screening technique and should 
have priority in any cervical cancer screening programme. We could not justify the 
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expense of routine typing of HPV when certain clinics do not do routine cytological 
screening. 
At present the typing of HPV is still an expensive technique that requires expertise 
and a Virology laboratory with a special interest in this particular field. A large 
scale typing programme would have to be rapid, inexpensive and provide both 
sensitive and specific information on the type of HPV present in a particular 
sample. Ideally patient material should also be obtained by a relatively non-invasive 
technique such as cytological sampling. (Roman and Fife, 1989). The current "gold 
standard" in the molecular typing of HPV is Southern blot hybridization. This is a 
slow and expensive procedure requiring relatively large amounts of DNA which are 
usually only obtainable by cervical biopsy. This technique is therefore not ideal for 
determining the prevalence of different types of HPV infection in the general 
population. 
Caution must be exercised in the interpretation of the results obtained from the 
typing of HPV as certain "high risk" HPV types have been found in normal 
cervical tissue and the clinical interpretation of these results is uncertain. (Young et 
al., 1989). It is therefore probably more appropriate to treat the patient according 
to the degree of cervical intraepithelial neoplasia rather that the type of HPV 
infection. 
The typing of HPV in Cape Town with currently available cloned HPV probes 
would be of limited value as many of our patients have "unclas~ified" HPV types. 
Further characterization of these "unclassified" HPV types would be of great value 
to determine the prevalent strains of HPV in our region. 
Although a large scale typing programme is not indicated at present, especially in 
the South African situation, the molecular typing of human papillomaviruses in 
patients with malignant and pre-malignant cervical disease as well as in women 
with no apparent cervical pathology provides valuable information. Cancer of the 
cervix is the second most common cancer amongst women world-wide. 
(Armstrong, 1987). This disease therefore contributes significantly to the morbidity 
and mortality of women world-wide. A thorough understanding of the nature of the 
disease and its causal agent(s) is necessary for any control programme 
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6. Conclusions 
HPV DNA was detected in a total of 44 % of patients with invasive carcinoma of 
the cervix in Cape Town by Southern blot hybridization. HPV 16 DNA was 
detected in a total of 16/86 ( 19 % ) patients by Southern blot hybridization or the 
polymerase chain reaction. This is somewhat less than what has been reported in 
many studies. (Durst et al., 1983; Mccance et al., 1985). However, the 
geographical variation in the prevalence of HPV 16 infection has been well 
documented with the some areas reporting only 11 % of patients with invasive 
carcinoma of the cervix with detectable HPV 16 DNA detectable by Southern blot 
hybridization. (Fukushima et al., 1985) 
Biopsies from patients with invasive carcinoma of the cervix in Cape Town showed 
a similar detection rate of HPV DNA when compared to a study on cervical 
intraepithelial neoplasia grade 3 in Cape Town. (Williamson et al., 1989). This, 
together with the fact that the application of a more sensitive technique, the 
polymerase chain reaction, did not significantly increase our detection rate of HPV 
16 DNA in biopsies obtained from patients with invasive carcinoma of the cervix, 
indicates a truly low prevalence of HPV 16 in this region. 
Further characterization of the "unclassified" HPV types detected in this study will 
determine whether these are novel HPV types which are important in the 
development of genital neoplasia in our geographical region 
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7. Figures 
Figure 4: Autoradiograph demonstrating the presence of a HPV 16 prototype 
and a HPV 16 "variant". 
Autoradiograph of agarose gel electrophoresis fractionated Pstl fragments of total 
DNA from biopsies obtained from patients with carcinoma of the cervix. The 
biopsy DNA was hybridized with cloned HPV 16 DNA under conditions of 
moderate stringency. 
Lane 1: HPV 16 "variant" 
Lane 2: Carcinoma of the cervix DNA negative for HPV 16 
Lane 3: HPV 16 prototype 
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Figure 5: Autoradiograph showing a HPV 16 prototype, a HPV 16 prototype 
together with additional bands and an unclassified HPV. 
Autoradiograph of agarose gel electrophoresis fractionated PstI fragments of total 
DNA from biopsies obtained from patients with carcinoma of the cervix. The 
biopsy DNA was hybridized with cloned HPV 16 DNA under conditions of 
moderate stringency. 
Figure 5a: "Unclassified" HPV (possibly an integrated HPV 16) 
Figure 5 b: Lane 1: HPV 16 prototype. 
Lane 2: HPV 16 prototype, together with additional 
bands (marked with arrows) 
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6" 7 
Figure 6: Autoradiograph demonstrating a HPV 33 prototype, together with 
an unclassified HPV type. 
Autoradiograph of agarose gel electrophoresis fractionated DNA fragments of total 
DNA from biopsies from patients with carcinoma of the cervix. The biopsy DNA 
was hybridized with cloned HPV 33 DNA under conditions of moderate stringency. 
Lane 1: HPV 33 prototype 
Lanes 2, 4 and 6: Biopsies containing HPV 16 DNA cross-hybridizing with the 
cloned HPV 33 probe. 
Lane 10: Unclassified HPV type. 
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Figure 7: Autoradiograph demonstrating a HPV 18 prototype. 
Autoradiograph of agarose gel electrophoresis fractionated Pstl fragments of total 
DNA from biopsies from patients with carcinoma of the cervix. The biopsy DNA 
was hybridized with cloned HPV 18 DNA under conditions of moderate stringency. 
The left hand lane contains no detectable HPV 18 DNA. The right hand lane shows 
a biopsy containing HPV 18 DNA from a patient with an adenocarcinoma of the 
cervix. 
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Figure 8: Autoradiograph showing selective DNA amplification of HPV 16. 
Autoradiograph of an agarose gel electrophoresis of amplified HPV 16 
DNA sequences using the polymerase chain reaction. 
Lane 1: Negative control (No DNA) 
Lane 2: Positive control from a patient with detectable HPV 16 DNA on Southern 
blot hybridization. 
Lanes 8, 11 and 13: Amplified HPV 16 sequences in biopsies with no detectable 
HPV 16 DNA on Southern blot hybridization. 
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Figure 9: Two autoradiographs comparing conditions to suppress background 
radioactivity. 
Figure 9a: The nylon membrane was treated with a 5 % solution of a commercial 
blocking agent (Boehringer Mannheim, FRG) dissolved in 6xSSC with 30% 
formamide and 10 % Dextran sulphate. 
Figure 9b: This shows a nylon membrane treated with a pre- hybridization solution 




Pstl die;estion of Human Papillomaviruses! 
HPV 16 HPV 18 HPV31 HPV33 HPV35 
MW (bp) 
2818 6337 2830 4605 4560 
1776 555 1650 2011 1770 
1549 457 1570 1173 530 
1063 441 1100 120 440 
483 67 450 400 
216 200 
100 
*Data correlated from the Papillomavirus reference· chart compiled by E-M De 
Villiers. 
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Pstl analysis and nucleotide sequence of HPV 16* 
Pstl fragment Nucleotide sequence 
2818 875 - 3692 
1776 7003 - 875 
1549 5238 - 6787 
1063 3692 - 4755 
483 4755 - 5238 
216 6787 - 7003 
*From Baker et al, 1987 
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Open Readine Frames of HPV 16! 
Open Readine Frame First nucleotide Nucleotide precedine 
Stop Codon 
Ela 859 1167 
Elb 1104 2810 
E2 2725 3849 
E4 3332 3616 
E5 3863 4096 
E6 65 556 
E7 554 855 
Ll 5526 7151 
L2 4133 5653 
* From Baker et al, 1987 
64 
9. References 
1. Armstrong B. Human papillomavirus and cervical cancer. Lancet 1988; i: 
756 - 757. 
2. Barnes MD, Delgardo G, Kurman RJ, Petrilli ES, Smith DM, Ahmed S, 
Lorincz AT, Temple GF, Jenson AB and Lancaster WD. Possible 
prognostic significance of human papillomavirus type in cervical cancer. 
Gynecologic Oncology 1988; 29: 267 - 273. 
3. Baker CC. Sequence analysis of papillomavirus genomes In: Salzman N 
and Howley P, ed. The Papovaviridae Vol. 2. Appendix Plenum Press, 
New York, 1987: 321 - 384. 
4. Berger SL and Kimmel AR. A guide to molecular cloning techniques. 
Academic Press,Inc. 1987. 
5. Beaudenon S, Kremsdorf D, Croissant 0, Jablonska S, Wain- Hobson S, 
and Orth G. A novel type of human papillomavirus associated with genital 
neoplasias. Nature 1986; 321: 247-248 
6. Beckman AM, Meyerson D, Daling JR, Kiviat NB, Fenoglio CM and 
McDougall JK. Detection of human papillomavirus DNA in human genital 
condylomas by in-situ hybridization with biotinylated probes. J. Med. Virol. 
1985; 16: 265 - 273. 
7. Boshart M, Gissman L, lkenberg H, Kleinheinz A, Scheurien W. and zur 
Hausen H. A new type of papillomavirus DNA, its presence in genital 
cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 
1984; J: 1151-1157. 
8. Campo M.S. Viral and cellular oncogenes in papillomavirus- associated 
cancers. British Journal of Cancer 1988; 58: Suppl. IX, 80-84. 
9. Caussy D, Orr W, Daya D, Roth P, Reeves Wand Rawls W. Evaluation 
of methods for detecting human papillomavirus deoxyribonucleotide 
sequences in clinical specimens. J. Clin. Microbiol. 1988; 26: 236 - 243. 
65 
10. Chen EY, Howley PM, Levinson AD and Beeburg PH. The primary 
structure and genetic organization of bovine papillomavirus type 1 genome. 
Nature 1982; 299: 529 - 535. 
11. Choo KB, Pan CC, and Han SH. Integration of Human Papillomavirus 
Type 16 into cellular DNA of cervical carcinoma: Preferential deletion of 
the E2 gene and invariable retention of the Long Control Region and the 
E6/E7 Open Reading Frames. Virology 1987; 161: 259-261. 
12. Choo KB, Pan CC, Liu MS, Ng HT, Chen CP, Lee YN, Chao CF, 
Meng CL, Yeh Mand Han SH. Presence of episomal and integrated human 
papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 1987; 
21 : 101 - 107. 
13. Coggin JR and zur Hausen H. Workshop on papillomavirus and cancer. 
Cancer Res. 1979; 39; 545 - 546. 
14. Cronje HS. Cervical cancer - have we lost the battle? SAMJ 1989; 76: 
587. 
15 Crum CP, Ikenberg H, Rochart RM and Gissman L. Human 
papillomavirus type 16 and early cervical neoplasia. N. Engl. J. Med. 1984; 
310: 880 - 883. 
16. Crum CP, Mitao M, Levine RV and Silverstein S. Cervical 
papillomaviruses segregate within morphologically distinst precancerous 
lesions. J. Virol. 1985; 54: 675 - 681. 
17. De Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, 
Wahrendorf J, Papendick U and zur Hausen H. Analysis of benign and 
malignant urogenital lesions by labelling of cellular DNA. Med. Microbiol. 
Immunol. 1986; 174: 281 - 286. 
18. De Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, 
Wahrerdorf J, Papendick V and zur Hausen H. Human papillomavirus 
infections in women with and without abnormal cervical cytology. Lancet 
1987; ii: 703 - 705. 
66 
19. De Villiers EM. Heterogeneity of the human papillomavirus group. 
J. Virol. 1989; 63: 4898 - 4903. 
20. Durst M, Gissman L, Ikenberg Hand zur Hausen H. A papillomavirus 
DNA from a cervical carcinoma and its prevelence in cancer biopsy samples 
from different geographic regions. Proc. Natl. Acad. Sci. USA 1983; 80: 
3812-3815. 
21. Durst M, Kleinheinz A, Hotz M and Gissmann L. The physical state of . 
human papillomavirus type 16 DNA in benign and malignant genital 
tumours. J. Gen. Virol. 1985; 66: 1515 - 1522. 
22. Durst M, Croce C.M, Gissmann L, Schwartz E and Huebner K. 
Papillomavirus sequences integrate near cellular oncogenes in some cervical 
carcinomas. Proc. Natl. Acad. Sci. USA 1987; 84: 1070 - 1074. 
23. Durst M, Gallagen D, Jay G and Rhim JS. Glucocorticoid- enhanced 
neoplastic transformation by Human Papillomavirus type 16 and activated 
ras oncogene. Virology 1989; 173: 767 - 771. 
24. Dvoretzky I, Shober R, Chattopadhyay SK. and Lowy A quantitive in 
vitro focus assay for Bovine papillomavirus. Virology 1980; 103: 369. 
25. Eisenstein BI. The polymerase chain reaction. A new method of using 
molecular genetics for medical diagnosis. N. EngLJ. Med. 1990; 322; 178 
- 180. 
26. Fukushima M, Okagaki T, Twiggs LB, Clark B, Zachow KR, Ostrow 
RS and Faras AJ. Histological types of carcinoma of the uterine cervix and 
the detectability of human papillomavirus DNA. Cancer Res. 1985; 45: 
3252 - 3255. 
27. Gage JR, Meyers C and Wettstein F. The E7 proteins of the 
nononcogenic human papillomavirus type 6b and of the oncogenic HPV-16 
differ in retinoblastoma protein binding and other properties. J. Virol. 1990; 
64: 723 - 730. 
67 
28. Gergety L, Czegledy J. and Hernady Z. (Letter) Human papillomavirus 
frequency in norman cervical tissue. Lancet 1987; ii: 513. 
29. Giro I and Danos 0. Papillomavirus genomes: from sequence data to 
biological properties Trends Genetics 1986; 2: 227 -232. 
30. Henderson B.E. Establishment of an Association between a virus and a 
human cancer. J. Natl. Cancer Inst. 1989; .81: 20-217. 
31. Howley P. Papillomavirinae and their replication. In: Fields BN and 
Knipe DM. ed. Field's Virology. Raven Press, New York. 1990: 1625 -
1650. 
32. Jarret WFH, Campo MS, Blaxter ML, O'Neil BW, Laird HM, Moar 
M.H. and Sartirana ML. Ailimentary Fibropapilloma in cattle: A 
spontaneous tumour, nonpermissive for papillomavirus replication. J. Natl. 
Cancer Inst. 1984; 73: 499 - 504. 
33. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldosky U, 
Schneweis K, Seedorf K and Gissman. Antibodies against the human 
papillomavirus type 16 early proteins in human sera: Correlation of anti-E7 
reactivity with cervical cancer. J. Natl. Cancer Inst. 1989; .81: 1698 - 1704. 
34. Kahn T, Schwarz E and zur Hausen H. Molecular cloning and 
characterisation of the DNA of a new human papillomaviius (HPV 30) from 
a laryngeal carcinoma. Int. J. Cancer 1986; 37: 61 - 65. 
35. Kurman RJ, Schiffman MH, Lancaster W, Reid R, Jenson B, Temple 
GF and Lorincz. Analysis of individual human papillomavirus types in 
cervical neoplasia: A possible role for HPV 18 in rapid progression. Am. J. 
Obstet Gynecol 1988; 159: 293 - 296. 
36. Lorincz A, Lancaster Wand Temple G. Cloning and characterization of 
the DNA of a new human papillomavirus from a woman with dysplasia of 
the uterine cervix. J. Virol. 1986; 58; 225-229. 
68 
37. Lorincz A, Quinn A, Goldsborough M, McAllister P and Temple G. 
Human papillomavirus type 56: a new virus detected in cervical cancers. J. 
Gen. Virol. 1989; 70: 3099 - 3104. 
38. Maniatis T, Fritsch EF and Sambrook. In: Molecular cloning. A 
laboratory manual. Cold Spring Harbour, 1982. 
39. Marx J. How DNA viruses may cause cancer. Science 1989; 243: 1012 
-1013 
40. Matsukura T, Koi Sand Sugase M. Both episomal and integrated forms 
of Human Papillomavirus 16 are involved in invasive cervical cancer. 
Virology 1989; 172: 63 - 71. 
41. Mccance DJ, Campion MJ, Clarkson PK, Chesters PM, Jenkins D and 
Sing A. Br. J. Obtste. Gynecol. 1985; 92: 1101 - 1105. 
42. Melnick JL, Rawls WE and Adam E. Cervical cancer. In: Evans ed. 
Viral infections of humans. Plenum Press, New York, 1989:687 - 704. 
43. Munoz N, Bosch X and Kaldor JM. Does human papillomavirus cause 
cervical cancer? The state of the epidemiological evidence. Br. J. Cancer 
1988; 57: 1 -5. 
44. Naghashfar Z, Rosenshein N, Lorincz A, Buscema J and Shah K. 
Characterization of human papillomavirus type 45, a new type 18- related 
virus of the genital tract. J. Gen. Virol. 1987; 68: 3073-3079. 
45. Nuovo G, Crum C, De Villiers E.M, Levine R and Silverstein S. 
Isolation of a novel human papillomavirus (Type 51) from a cervical 
condyloma. J. Virol. 1988; 62: 1452-1455. 
46. Petterson U, Ahola H, Stenlund A and Moreno-Lopwz J. In: Salzman N 
and Howley Ped. The Papovaviridae, Volume 2. Plenum Press, New York, 
1987: 67 - 103. 
69 
47. Pfister H. Papillomaviruses: General description, taxonomy and 
classification. In: Salzman N and Howley P ed. The Papovaviridae, 
Volume 2. Plenum Press, New York, 1987a: 1 - 30. 
48. Pfister H. Human Papillomaviruses and genital cancer. Adv. Cancer 
Res. 1987b; 48: 113-147. 
49. Reeves WC, Caussy D, Brinton L, Brinton L, Brenes M, Montalvan P, 
Gomez B, De Britton R, Morice E, Gaitan E, Loo de Lao S and Rawls. 
Case-control study of human papillomaviruses and cervical cancer in Latin 
America. Int. J. Cancer 1987; 40: 450 - o7 3 454. 
50. Reeves WC, Brinton LA, Garcia M, Brenes MM, Herrero R, Gaitan E, 
Tenorio F, De Britton RC and Rawls WE. Human papillomavirus infection 
and cervical cancer in Latin America. N. Engl. J. Med. 1989; 320: 1437 -
1441. 
51. Riou G, Le MG, Doussal V, Barrois M, George Mand Haie C. C-myc 
proto-oncogene expression and the prognosis in early carcinoma of the 
uterine cervix. Lancet 1987; i: 761 - 763. 
52. Rotkin ID. A comparison review of key epidemiological studies in 
cervical cancer related to current searches for transmissible agents. Cancer 
Res. 1973; 33: 1353 - 1367. 
53. Roman A and Fife KH. Human papillomaviruses: Are we ready to 
type? Clin. Microbiol. Rev. 1989; 2: 166 - 190. 
54. Schaffer H and Sederoff RR. Improved estimation of DNA fragment 
lengths from agarose gels. Anaj. Biochem. 1981; 115: 113 - 122. 
55. Schneider-Maunoury S, Croissant O and Orth G. Integration of Human 
papillomavirus Type 16 DNA sequences: A possible early event in the 
progression of genital tumours. J. Virol. 1987; 61: 3295 - 3298. 
56. Seedorf K, Krammer G, Durst M, Suhai Sand Rowekamp W. Human 
papillomavirus type 16 sequence. Virology 1985; 145: 181 -185. 
70 
57. Shah KV and Howley PM. Papillomaviruses. In: Field BN and Knipe 
DM ed. Field's Virology. Raven Press, New York, 1990: 1651 - 1678. 
58. Shimoda K., Lorincz A., Temple G. and Lancaster W. Human 
papillomvirus type 52: A new virus associated with cervical neoplasia. J. 
Gen. Virol. 1988; 69: 2925-2928. 
59. Smith GE and Summers MD. The bidirectional transfer of DNA and 
RNA to nitrocellulose or diazobenzyloxymethyl-paper. Anal. Biochem. 
1980; 109: 123 - 129. 
60. Taichman LB and LaPorta RF. The expression of papillomaviruses in 
epithelial cells. In: Salzman NP and Howley P ed. The Papovaviridae 
Volume 2. Plenum press, New York, 1987: 109 - 134. 
61. Tidy J, Parry G, Ward P, Coleman D, Petro J, Malcolm A and Farrell 
P. High rate of human papillomavirus type 16 infection in cytologically 
normal cervices. Lancet 1989a; ii: 434. 
62. Tidy J, Voudsen K and Farrel P. Relation between infection with a 
subtype of HPV 16 and cervical neoplasia. Lancet 1989b; i: 1225-1227. 
63. Tidy J and Farrell P. Retraction: Human papillomavirus subtype 16b. 
Lancet 1989c; ii: 1535. 
64. Toon P, Wilson LP and Sharp DS. Human papillomavirus infection of 
the uterine cervix of women without cytological signs of cervical neoplasia. 
Br. Med. J. 1986; 293: 1261 - 1265. 
65. Wagatsukura M, Hashimoto Kand Matsukura T. Analysis of integrated 
Human Papillomavirus Type 16 DNA in cervical cancers: Amplification of 
viral sequences together with cellular flanking sequences. J. Virol 1990; 64: 
813-821. 
66. Williamson A-L, Dehaeck CMC and Soeters R. Typing of human 
papillomavirus in cervical intraepithelial neoplasia grade 3 biopsies from 
Cape Town. J. Med. Virol. 1989; 28: 146 - 149. 
71 
67. Yajima H, Noda T, De Villiers EM, Yajima A, Yamamoto K, Noda K 
and Ito Y. Isolation of a new type of human papillomavirus (HPV 52b) with 
a transforming activity fron cervical tissue. Cancer Res. 1988; 48: 7164-
7172. 
68. Young LS, Bevan IS, Johnson MA, Blomfield PI, Brombridge T, 
Maitland NG and Woodman CBJ. The polymerase chain reaction: a new 
epidemiological tool for investigating cervical human papillomavirus 
infection. Br. Med. J. 1989; 298: 14 - 18. 
69. zur Hausen H. Human genital cancer: Synergism between two virus 
infections or synergism between a virus infection and iniating events? 
Lancet 1982; ii: 1370 - 1371. 
70. zur Hausen H. The role of papillomaviruses in human anogenital 
cancer. In: Salzman N and Howley P. ed. The Papovaviridae Volume 2. 
Plenum Press, New York, 1987: 245 - 259. 
